 "Image via Shutterstock")
Granules USA, the wholly-owned subsidiary of Granules India Limited has entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International Plc to market the generic version of OTC omeprazole and sodium bicarbonate in the US.
The company said it was expecting the approval from the US FDA for this generic heart burn drug in July 2016. Par Pharmaceuticals' omeprazole and sodium bicarbonate is the generic equivalent of Merck/ MSD Consumer Care, Inc's Zegerid OTC.
“Granules is excited that, through this exclusive agreement with Par Pharmaceutical, we can strengthen our OTC product basket and widen our offerings in the North American store brand market for meeting retailers' and consumers' desire for competitive market choices and alternatives,” said Krishna Prasad Chigurupati, chairman and managing director of Granules India.
